About Thirty Madison
Thirty Madison is a Healthcare company based in New York (United States) founded in 2017 by Steven Gutentag and Demetri Karagas, and was acquired by Remedy Meds in September 2025. Virtual care and personalized treatments for chronic conditions are provided. Thirty Madison has raised $210 million across 4 funding rounds from investors including Elkstone, Alpha Partners and Health Quest Capital. The company has 191 employees. Thirty Madison was last valued at $1.04 billion in January 2025. Its chief executive, as recorded, is Demetri Karagas. Its focus areas include HealthTech, Healthcare Booking Platforms, Pharmacies and Drugs. Its competitors include Nurx, Icebreaker Health and PipelineRx; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2017 and based in New York, United States, Thirty Madison operates as a virtual-first healthcare platform. Specialized brands are offered for conditions such as mens hair loss through Keeps, migraines via Cove, allergies with Picnic, skin issues by Facet, and sexual health via NURX. Chronic conditions are addressed through accessible, tailored virtual services across the United States.
- Headquarters New York, United States
- Employees 191
- Founders Steven Gutentag, Demetri Karagas
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website thirtymadison.com
- Social LinkedIn X
- Acquired by Remedy Meds (Sep 2025)
- Total Equity Funding$210M (USD)
in 4 rounds
- Latest Funding Round$141M (USD), Series C
Jun 2021
- InvestorsElkstone
& 24 more
- Employee Count191
- Acquired byRemedy Meds
(Sep 2025)
Funding Insights of Thirty Madison
Thirty Madison has successfully raised a total of $210M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $141 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210M
- Total Rounds 4
- Last Round Series C — $141M
- First Round $2.75M
(May 2017)
- Investors Count 25
All 4 funding rounds of Thirty Madison with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $141M | Series C | $1B | Health Quest Capital | |
| Aug 2020 | $47M | Series B | – | Johnson & Johnson Innovation – JJDC, Polaris Partners | – |
| Oct 2018 | $15.25M | Series A | – | Maveron, Northzone | |
| May 2017 | $2.75M | Series A | – | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2021 | $1B | •••••••• |
Full valuation and stage history of Thirty Madison
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.04B (Jan 2025). 25 investors in total: 23 institutional and 2 angel.
Investors in Thirty Madison
Thirty Madison has secured backing from 25 investors, including venture fund and angel investors. Prominent investors backing the company include Elkstone, Alpha Partners and Health Quest Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Multi-asset investment management is provided for technology-enabled companies. | bracketcapital.com | Los Angeles, United States | ||
Venture capital fund focused on multiple sectors | mousse-partners.com | New York, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Multiple sectors are targeted for venture capital investments by Greycroft. | greycroft.com | New York, United States | ||
Early-stage startups are funded by Northzone venture capital. | northzone.com | London, United Kingdom | ||
Venture capital investments in consumer businesses, emphasizing technology and human behavior. | maveron.com | |||
Private equity investments are directed toward Europe by Steadfast Capital. | steadfastcapital.de | Frankfurt Am Main, Germany | ||
Two River is engaged in building life science companies. | tworiver.com | New York, United States |
Investor details for Thirty Madison
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Thirty Madison
2 people are tracked at Thirty Madison (2 in leadership); the tracked headcount is 191.
| Name | Role | Group |
|---|---|---|
Steven Gutentag | Co-Founder | Leadership |
Demetri Karagas | Co-Founder & CEO | Leadership |
Complete people profiles for Thirty Madison
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Thirty Madison
5 dated milestones of Thirty Madison across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Thirty Madison is founded.
- Funding First funding round of $2.7M.
- Funding Latest funding round, Series C, of $141.0M.
- Milestone Reaches Unicorn status.
- Exit Acquired by Remedy Meds.
Competitors of Thirty Madison
Thirty Madison has 3 listed competitors in our database, 3 of them funded. They include Nurx, Icebreaker Health and PipelineRx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nurx.com | 2015 | San Francisco, United States | $95.92M | 400 | Online prescriptions and delivery of contraceptives and PrEP are facilitated. | |
| lemonaidhealth.com | 2014 | San Francisco, United States | $55.46M | 182 | Provider of remote patient consultation services and online delivery of medical care products | |
| pipelinerx.com | 2009 | San Francisco, United States | $27.34M | 206 | 24/7 telepharmacy and software solution provider |
Detailed competitors of Thirty Madison
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Thirty Madison
The website of Thirty Madison (thirtymadison.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▼ 29.2% vs previous month
Websites whose visitors overlap most with Thirty Madison. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
jobs.lever.co | jobs.lever.co | 100% | #4,880 | – | |
| linkedin.com | 44% | 1.9B | #18 | View details |
Top companies in Digital Health & Telemedicine
3 companies that operate in the same segment as Thirty Madison (Digital Health & Telemedicine) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
An application is provided for comparing prescription drug prices nationwide. | 2011 | Santa Monica, California, United States | USD 22.21 M | USD 796.85 M | 1,063 | |
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Alto Pharmacy is focused on providing convenient prescription delivery services. | 2015 | San Francisco, California, United States | USD 591.64 M | 802 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Thirty Madison
Complete news archive for Thirty Madison
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thirty Madison
Thirty Madison was founded in 2017.
Thirty Madison is headquartered in New York, United States. It is registered at New York, New York, United States.
Demetri Karagas is the CEO of Thirty Madison, as recorded in our data. They have also founded this company.
Thirty Madison is a funded company, having raised a total of $210M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.75M, raised on May 2017.
Thirty Madison has 191 employees.
Founded in 2017 and based in New York, United States, Thirty Madison operates as a virtual-first healthcare platform. Specialized brands are offered for conditions such as mens hair loss through Keeps, migraines via Cove, allergies with Picnic, skin issues by Facet, and sexual health via NURX. Chronic conditions are addressed through accessible, tailored virtual services across the United States.
Thirty Madison's top competitors include Icebreaker Health, Nurx and PipelineRx.
Thirty Madison has 25 investors. Key investors include Elkstone, Alpha Partners, Health Quest Capital, Bracket Capital, and Mousse Partners.
The valuation of Thirty Madison is $1.04B as of Jan 2025.
Yes. Thirty Madison was acquired by Remedy Meds in September 2025.